RBC Capital raised the firm’s price target on Crispr Therapeutics (CRSP) to $50 from $42 and keeps a Sector Perform rating on the shares after its better than expected Q3 earnings. The firm “appreciate all the progress” but still remains on the sidelines with a cautious stance on Casgevy’s launch and pending further progress on the rest of the pipeline, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics price target lowered to $44 from $52 at Baird
- Crispr Therapeutics price target lowered to $69 from $70 at JPMorgan
- Crispr Therapeutics AG: Hold Rating Amid Financial Challenges and Mixed Pipeline Progress
- Crispr Therapeutics price target lowered to $50 from $52 at Clear Street
- Crispr Therapeutics reports Q3 EPS ($1.17), consensus ($1.29)